Targeted treatment trials for tuberous sclerosis and autism: No longer a dream

Current Opinion in Neurobiology

Volumn 22, Issue 5, 2012, Pages 895-901

  Sahin, Mustafa ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ARBACLOFEN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEMANTINE; MINOCYCLINE; OCTAHYDRO 4 HYDROXY 4 [(3 METHYLPHENYL)ETHYNYL] 1H INDOLE 1 CARBOXYLIC ACID METHYL ESTER; RAPAMYCIN; RECOMBINANT SOMATOMEDIN C; RG 1662; RIVASTIGMINE; RO 4917523; UNCLASSIFIED DRUG; VIGABATRIN;

AUTISM; CELL CULTURE; COGNITIVE DEFECT; CORONARY ARTERY OBSTRUCTION; DISEASE MODEL; DOWN SYNDROME; DRUG TARGETING; EPILEPSY; GENETIC DISORDER; GRAFT REJECTION; HEMANGIOFIBROMA; HUMAN; INTELLECTUAL IMPAIRMENT; KIDNEY HEMANGIOMYOLIPOMA; LEARNING DISORDER; LYMPHANGIOLEIOMYOMATOSIS; MEMORY DISORDER; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RETT SYNDROME; REVIEW; RHABDOMYOMA; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TUBEROUS SCLEROSIS;

AUTISTIC DISORDER; HUMANS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS;

EID: 84868200593     PISSN: 09594388     EISSN: 18736882     Source Type: Journal    
DOI: 10.1016/j.conb.2012.04.008     Document Type: Review

References (59)

1. Ganz M. The costs of autism. Understanding Autism: From Basic Neuroscience to Treatment 2006, 475-502. Taylor & Francis. S.O. Moldin, J.L.R. Rubenstein (Eds.).
2. Kanner L. Autistic disturbances of affective contact. Nervous Child 1943, 2:217-250.
3. Zoghbi H.Y. Postnatal neurodevelopmental disorders: meeting at the synapse?. Science 2003, 302:826-830.
4. Bauman M.L., Kemper T.L. Neuroanatomic observations of the brain in autism: a review and future directions. Int J Dev Neurosci 2005, 23:183-187.
5. Courchesne E., Redcay E., Morgan J.T., Kennedy D.P. Autism at the beginning: microstructural and growth abnormalities underlying the cognitive and behavioral phenotype of autism. Dev Psychopathol 2005, 17:577-597.
6. Freitag C.M., Staal W., Klauck S.M., Duketis E., Waltes R. Genetics of autistic disorders: review and clinical implications. Eur Child Adolesc Psychiatry 2010, 19:169-178.
7. Ronald A., Hoekstra R.A. Autism spectrum disorders and autistic traits: a decade of new twin studies. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2011, 156:255-274.
8. Shen Y., Dies K., Holm I., Bridgemohan C., Sobeih M., Caronna E., Miller K., Frazier J., Silverstein I., Picker J., et al. Clinical genetic testing for patients with autism spectrum disorders. Pediatrics 2010, 125(4):e727-e735. peds.2009-1684v2001.
9. Schaaf C.P., Zoghbi H.Y. Solving the autism puzzle a few pieces at a time. Neuron 2011, 70:806-808.
10. Curatolo P., Bombardieri R., Jozwiak S. Tuberous sclerosis. Lancet 2008, 372:657-668.
11. Crino P.B., Nathanson K.L., Henske E.P. The tuberous sclerosis complex. N Engl J Med 2006, 355:1345-1356.
12. Jeste S.S., Sahin M., Bolton P., Ploubidis G.B., Humphrey A. Characterization of autism in young children with tuberous sclerosis complex. J Child Neurol 2008, 23:520-525.
13. DiMario F.J. Brain abnormalities in tuberous sclerosis complex. J Child Neurol 2004, 19:650-657.
14. Kwiatkowski D.J., Manning B.D. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 2005, R251-R258. (14 Spec No. 2).
15. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
16. Ruvinsky I., Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 2006, 31:342-348.
17. Kelleher R.J., Bear M.F. The autistic neuron: troubled translation?. Cell 2008, 135:401-406.
18. Tworetzky W., McElhinney D.B., Margossian R., Moon-Grady A.J., Sallee D., Goldmuntz E., van der Velde M.E., Silverman N.H., Allan L.D. Association between cardiac tumors and tuberous sclerosis in the fetus and neonate. Am J Cardiol 2003, 92:487-489.
19. Datta A.N., Hahn C.D., Sahin M. Clinical presentation and diagnosis of tuberous sclerosis complex in infancy. J Child Neurol 2008, 23:268-273.
20. Choi Y.J., Di Nardo A., Kramvis I., Meikle L., Kwiatkowski D.J., Sahin M., He X. Tuberous sclerosis complex proteins control axon formation. Genes Dev 2008, 22:2485-2495.
21. Li Y.H., Werner H., Puschel A.W. Rheb and mTOR regulate neuronal polarity through Rap1B. J Biol Chem 2008, 283:33784-33792.
22. Morita T., Sobue K. Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR-p70S6K pathway. J Biol Chem 2009, 284:27734-27745.
23. Nie D., Di Nardo A., Han J.M., Baharanyi H., Kramvis I., Huynh T., Dabora S., Codeluppi S., Pandolfi P.P., Pasquale E.B., et al. Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat Neurosci 2010, 13:163-172.
24. Meikle L., Talos D.M., Onda H., Pollizzi K., Rotenberg A., Sahin M., Jensen F.E., Kwiatkowski D.J. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci 2007, 27:5546-5558.
25. Kumar V., Zhang M.X., Swank M.W., Kunz J., Wu G.Y. Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J Neurosci 2005, 25:11288-11299.
26. Jaworski J., Spangler S., Seeburg D.P., Hoogenraad C.C., Sheng M. Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway. J Neurosci 2005, 25:11300-11312.
27. Tavazoie S.F., Alvarez V.A., Ridenour D.A., Kwiatkowski D.J., Sabatini B.L. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat Neurosci 2005, 8:1727-1734.
28. Meikle L., Pollizzi K., Egnor A., Kramvis I., Lane H., Sahin M., Kwiatkowski D.J. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 2008, 28:5422-5432.
29. Wang Y., Barbaro M.F., Baraban S.C. A role for the mTOR pathway in surface expression of AMPA receptors. Neurosci Lett 2006, 401:35-39.
30. Bateup H.S., Takasaki K.T., Saulnier J.L., Denefrio C.L., Sabatini B.L. Loss of Tsc1 in vivo impairs hippocampal mGluR-LTD and increases excitatory synaptic function. J Neurosci 2011, 31:8862-8869.
31. Auerbach B.D., Osterweil E.K., Bear M.F. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 2011, 480:63-68.
32. von der Brelie C., Waltereit R., Zhang L., Beck H., Kirschstein T. Impaired synaptic plasticity in a rat model of tuberous sclerosis. Eur J Neurosci 2006, 23:686-692.
33. Minshew N.J., Williams D.L. The new neurobiology of autism: cortex, connectivity, and neuronal organization. Arch Neurol 2007, 64:945-950.
34. Geschwind D.H., Levitt P. Autism spectrum disorders: developmental disconnection syndromes. Curr Opin Neurobiol 2007, 17:103-111.
35. Ehninger D., Han S., Shilyansky C., Zhou Y., Li W., Kwiatkowski D.J., Ramesh V., Silva A.J. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med 2008, 14:843-848.
36. Goorden S.M., van Woerden G.M., van der Weerd L., Cheadle J.P., Elgersma Y. Cognitive deficits in Tsc1+/- mice in the absence of cerebral lesions and seizures. Ann Neurol 2007, 62:648-655.
37. Zeng L.H., Ouyang Y., Gazit V., Cirrito J.R., Jansen L.A., Ess K.C., Yamada K.A., Wozniak D.F., Holtzman D.M., Gutmann D.H., et al. Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. Neurobiol Dis 2007, 28:184-196.
38. Zhou J., Shrikhande G., Xu J., McKay R.M., Burns D.K., Johnson J.E., Parada L.F. Tsc1 mutant neural stem/progenitor cells exhibit migration deficits and give rise to subependymal lesions in the lateral ventricle. Genes Dev 2011, 25:1595-1600.
39. Jaeschke A., Hartkamp J., Saitoh M., Roworth W., Nobukuni T., Hodges A., Sampson J., Thomas G., Lamb R. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J Cell Biol 2002, 159:217-224.
40. Dan H.C., Sun M., Yang L., Feldman R.I., Sui X.M., Ou C.C., Nellist M., Yeung R.S., Halley D.J., Nicosia S.V., et al. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 2002, 277:35364-35370.
41. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002, 4:648-657.
42. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 2002, 10:151-162.
43. Potter C.J., Pedraza L.G., Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 2002, 4:658-665.
44. Franz D.N., Leonard J., Tudor C., Chuck G., Care M., Sethuraman G., Dinopoulos A., Thomas G., Crone K.R. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006, 59:490-498.
45. Krueger D.A., Care M.M., Holland K., Agricola K., Tudor C., Mangeshkar P., Wilson K.A., Byars A., Sahmoud T., Franz D.N. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010, 363:1801-1811.
46. Bissler J.J., McCormack F.X., Young L.R., Elwing J.M., Chuck G., Leonard J.M., Schmithorst V.J., Laor T., Brody A.S., Bean J., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008, 358:140-151.
47. Dabora S.L., Franz D.N., Ashwal S., Sagalowsky A., DiMario F.J., Miles D., Cutler D., Krueger D., Uppot R.N., Rabenou R., et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS One 2011, 6:e23379.
48. Davies D.M., de Vries P.J., Johnson S.R., McCartney D.L., Cox J.A., Serra A.L., Watson P.C., Howe C.J., Doyle T., Pointon K., et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 2011, 17:4071-4081.
49. McCormack F.X., Inoue Y., Moss J., Singer L.G., Strange C., Nakata K., Barker A.F., Chapman J.T., Brantly M.L., Stocks J.M., et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011, 364:1595-1606.
50. Tiberio D., Franz D.N., Phillips J.R. Regression of a cardiac rhabdomyoma in a patient receiving everolimus. Pediatrics 2011, 127:e1335-e1337.
51. Hofbauer G.F., Marcollo-Pini A., Corsenca A., Kistler A.D., French L.E., Wuthrich R.P., Serra A.L. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol 2008, 159:473-475.
52. Haemel A.K., O'Brian A.L., Teng J.M. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol 2010, 146:715-718.
53. -1) in two patients with tuberous sclerosis. Br J Dermatol 2011, 165:922-923.
54. Kaufman McNamara E., Curtis A.R., Fleischer A.B. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin. J Dermatol Treat 2012, 23:46-48.
55. DeKlotz C.M., Ogram A.E., Singh S., Dronavalli S., MacGregor J.L. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol. Arch Dermatol 2011, 147:1116-1117.
56. Jozwiak S., Kotulska K., Domanska-Pakiela D., Lojszczyk B., Syczewska M., Chmielewski D., Dunin-Wasowicz D., Kmiec T., Szymkiewicz-Dangel J., Kornacka M., et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol 2011, 15:424-431.
57. Widjaja E., Simao G., Mahmoodabadi S.Z., Ochi A., Snead O.C., Rutka J., Otsubo H. Diffusion tensor imaging identifies changes in normal-appearing white matter within the epileptogenic zone in tuberous sclerosis complex. Epilepsy Res 2010, 89:246-253.
58. Peters J.M., Sahin M., Vogel-Farley V.K., Jeste S.S., Gregas M.C., Prabhu S.P., Scherrer B., Warfield S.K. Loss of white matter microstructural integrity is associated with adverse neurological outcome in tuberous sclerosis complex. Acad Radiol 2012, 19:17-25.
59. Huang H.S., Allen J.A., Mabb A.M., King I.F., Miriyala J., Taylor-Blake B., Sciaky N., Dutton J.W., Lee H.M., Chen X., et al. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature 2012, 481:185-189.